(Posted By: Josi Creek)
February 05, 2010

Feb. 5 (Bloomberg) -- Biogen Idec Inc. and Elan Corp.’s multiple sclerosis drug Tysabri has been linked to 31 cases of a deadly brain infection and eight deaths since it returned to the market in 2006, U.S. regulators said.

That number of infections and deaths won’t change the 1 in 1,000 infection rate currently on the drug’s label, the U.S. Food and Drug Administration said today in a notice on its Web site. The prescribing information will be updated, including a new comparison to infection rates overseas.

To read the full story, click here.